Dynamic Susceptibility Contrast MRI for Evaluation of Patients With High-Grade Glioma: Need for Multicenter Clinical Trial Validation.
Journal articles
- Journal Article
Barboriak, DP
Published in: AJR Am J Roentgenol
January 2026
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
AJR Am J Roentgenol
DOI
EISSN
1546-3141
Publication Date
January 2026
Volume
226
Issue
1
Start / End Page
e2532940
Location
United States
Related Subject Headings
- Nuclear Medicine & Medical Imaging
- 3202 Clinical sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Barboriak, D. P. (2026). Dynamic Susceptibility Contrast MRI for Evaluation of Patients With High-Grade Glioma: Need for Multicenter Clinical Trial Validation. AJR Am J Roentgenol, 226(1), e2532940. https://doi.org/10.2214/AJR.25.32940
Barboriak, Daniel P. “Dynamic Susceptibility Contrast MRI for Evaluation of Patients With High-Grade Glioma: Need for Multicenter Clinical Trial Validation.” AJR Am J Roentgenol 226, no. 1 (January 2026): e2532940. https://doi.org/10.2214/AJR.25.32940.
Barboriak DP. Dynamic Susceptibility Contrast MRI for Evaluation of Patients With High-Grade Glioma: Need for Multicenter Clinical Trial Validation. AJR Am J Roentgenol. 2026 Jan;226(1):e2532940.
Barboriak, Daniel P. “Dynamic Susceptibility Contrast MRI for Evaluation of Patients With High-Grade Glioma: Need for Multicenter Clinical Trial Validation.” AJR Am J Roentgenol, vol. 226, no. 1, Jan. 2026, p. e2532940. Pubmed, doi:10.2214/AJR.25.32940.
Barboriak DP. Dynamic Susceptibility Contrast MRI for Evaluation of Patients With High-Grade Glioma: Need for Multicenter Clinical Trial Validation. AJR Am J Roentgenol. 2026 Jan;226(1):e2532940.
Published In
AJR Am J Roentgenol
DOI
EISSN
1546-3141
Publication Date
January 2026
Volume
226
Issue
1
Start / End Page
e2532940
Location
United States
Related Subject Headings
- Nuclear Medicine & Medical Imaging
- 3202 Clinical sciences